e-Drug3D

334

OXANDROLONE

DISCONTINUED


INN
OXANDROLONE

cas 53-39-4
CLASS

METABOLISME
ANDROGENIC AND ANABOLIC AGENT
SYNTHETIC DERIVATIVE OF TESTOSTERONE
PROMOTE WEIGHT GAIN

ROUTE (list)

ORAL

ATC code

A14AA08

PK parameters

t1/2 13.3 HOUR

Target

TARGET ANDROGEN RECEPTOR

DrugCentral

Androgen receptor UNIPROT P10275 AR

Download SDF file (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[7,6-h]isochromen-7-one

Formula:
C19H30O3

Calculated chemical properties:

MW 306.43
NB_atoms 22
XLogP 3.54
PSA 47.228
NB_HD 1
NB_HA 3
fsp3 0.95
Lipinski(0=no;1=yes) 1

FDA
NDA 013718 (label) INN (OXANDROLONE) OXANDRIN (GEMINI LABS LLC) APPROVAL= AP YEAR= 1964 NEWMOLECULARENTITY DISCONTINUED OBSOLETE
NDA 076761 (label) INN (OXANDROLONE) OXANDROLONE (UPSHER SMITH LABS) APPROVAL= AP YEAR= 2006 DISCONTINUED
NDA 076897 (label) INN (OXANDROLONE) OXANDROLONE (SANDOZ) APPROVAL= AP YEAR= 2006 DISCONTINUED
NDA 077249 (pdf not found) INN (OXANDROLONE) OXANDROLONE (ROXANE) APPROVAL= AP YEAR= 2007 DISCONTINUED
NDA 077827 (pdf not found) INN (OXANDROLONE) OXANDROLONE (PAR PHARM) APPROVAL= AP YEAR= 2007 DISCONTINUED
NDA 078033 (pdf not found) INN (OXANDROLONE) OXANDROLONE (UPSHER SMITH LABS) APPROVAL= AP YEAR= 2007 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL